What have we really learned from 'LIBERATE' trial?

Constantine Dimitrakakis; Alexandra Tsigginou; Dimitris Keramopoulos; Aris Antsaklis

doi:10.1016/j.maturitas.2010.02.012

What have we really learned from 'LIBERATE' trial?

Maturitas. 2010 May;66(1):99-100. doi: 10.1016/j.maturitas.2010.02.012. Epub 2010 Mar 16.

Authors

Constantine Dimitrakakis¹, Alexandra Tsigginou, Dimitris Keramopoulos, Aris Antsaklis

Affiliation

¹ 1st Department of Ob/Gyn, Athens University Medical School, Athens, Greece. atsigginou@med.uoa.gr

PMID: 20236777
DOI: 10.1016/j.maturitas.2010.02.012

Abstract

LIBERATE trial reports that Tibolone use increases the risk of recurrence in breast cancer patients with vasomotor symptoms. However, there are some uncertainties and weak points in the study. Emerged questions are if interpretation of the results could be extrapolated to all breast cancer patients or there are specific subgroups that could use Tibolone without increasing relapse rate.

Publication types

Randomized Controlled Trial

MeSH terms

Breast Neoplasms / complications*
Estrogen Receptor Modulators / adverse effects*
Estrogen Receptor Modulators / therapeutic use
Female
Hot Flashes / complications
Hot Flashes / drug therapy*
Humans
Menopause
Neoplasm Recurrence, Local / etiology*
Norpregnenes / adverse effects*
Norpregnenes / therapeutic use

Substances

Estrogen Receptor Modulators
Norpregnenes
tibolone